All In Biotech

Drug Trial Radar · NCT05431543

Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine + Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia

Last checked: Nov 20, 2026Latest source record: Sep 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

59

Actual

Start

Aug 6, 2022

Primary completion

Dec 14, 2022

Study completion Dec 14, 2022

Sponsor

Lead sponsor
LENZ Therapeutics, IncAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 24, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Triple (care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 45 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.

Conditions

  • Presbyopia
  • Refractive Errors
  • Eye Diseases

Interventions

  • Aceclidine+Brimonidine combination ophthalmic solutionDrug

    LNZ101-combination ophthalmic solution

  • Aceclidine ophthalmic solutionDrug

    LNZ100- aceclidine ophthalmic solution

  • Vehicle proprietary ophthalmic solutionDrug

    Proprietary Vehicle ophthalmic solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance VisionTime frame: 1 hour post treatment

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • INSIGHT-2 Study Site #5

    Chandler, Arizona

  • INSIGHT-2 Study Site #3

    Glendale, California

  • INSIGHT-2 Study Site #1

    Andover, Massachusetts

  • INSIGHT-2 Study Site #2

    Memphis, Tennessee

  • INSIGHT-2 Study Site #4

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.